title: NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
authors.affiliation: National Institute for Health and Care Excellence, Spring Gardens, London SW1A 2BU, UK.
authors.forename: Martyn J
authors.initials: MJ
authors.lastname: Burke
authors.affiliation: National Institute for Health and Care Excellence, Spring Gardens, London SW1A 2BU, UK. Electronic address: elisabeth.george@nice.org.uk.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: George
authors.affiliation: National Institute for Health and Care Excellence, Spring Gardens, London SW1A 2BU, UK.
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Adler
mesh_terms: D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D017277:Drug Approval; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; C467566:pomalidomide; D000077269:Lenalidomide